Get all premium features to the best stock analysis tool

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT.

Investors need to pay close attention to AKBA stock based on the movements in the options market lately.

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 46,200 shares of Akebia's common stock on February 27, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript

Q4 2025 net product revenues of  $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass.